Form 4: Beam Therapeutics Executive Reports Stock Transaction

Bethany J. Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics Inc., reported a transaction involving 20,000 restricted stock units.

Summary

• Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., acquired 20,000 restricted stock units (RSUs) on March 31, 2026.
• These RSUs were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
• Each RSU represents the contingent right to receive one share of Beam Therapeutics' common stock.
• The RSUs vest in four equal installments over four years, contingent on continued service.
• Following this transaction, Cavanagh beneficially owns 54,813 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive stock grant and does not provide new financial information or strategic updates.

Positives

• Grant of 20,000 RSUs indicates continued incentive and retention efforts for key finance leadership.
• Vesting schedule over four years aligns executive compensation with long-term company performance.
• The reporting person's continued service is a prerequisite for vesting, suggesting commitment.

Negatives

• No direct financial performance metrics are disclosed in this Form 4 filing.

Risks

• Vesting of RSUs is subject to the reporting person's continued service, implying a risk of forfeiture if employment terminates.
• The value of the RSUs is tied to the performance of Beam Therapeutics' common stock, which is subject to market volatility.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future financial performance.

Industry Context

StockSavvy.ai notes that the issuance of RSUs to senior finance executives is a common practice in the biotechnology sector to align compensation with long-term value creation and retain critical talent.

Stakeholder Impact

• Shareholders: The grant of RSUs is a form of compensation, which can impact dilution if shares are issued upon vesting. The continued service requirement aligns executive interests with long-term shareholder value.

Next Steps

• RSUs will vest in four substantially equal installments on each of the first four anniversaries of the grant date, subject to continued service.

Key Dates

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Transaction, Stock Options, RSU, Executive Compensation, Securities Exchange Act